Clinical trials: Dementia
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143).
- Trial name
- NCT00998764
- Testing
- Bapineuzumab 0.5 mg/kg
- Where
- 184 sites in United States, Argentina and 17 more
- Volunteers
- 494 people
- Sponsor
- Pfizer
Alzheimer Disease, Cognition Disorder
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856
The multiple ascending dose (MAD) design of the study is based on the aim to study safety, tolerability, PK and pharmacodynamics of selected doses of ACD856 in a limited number of healthy volunteers.
- Trial name
- NCT05077501
- Testing
- ACD856
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Alzheimer's Disease
Extension Study of Participants From SPG302-ALZ-101
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)
- Trial name
- NCT06833281
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Spinogenix
Alzheimer's Disease
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.
- Trial name
- NCT01825330
- Testing
- TMS and cognitive stimulation
- Where
- 10 sites in United States, Israel
- Volunteers
- 131 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease, Dementia
Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
The purpose of this study is to evaluate the safety of 2 fixed doses of EVP-6124 hydrochloride (HCl) compared to placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease who are concurrently receiving stable…
- Conditions
- Alzheimer's Disease, Dementia, Cognition
- Trial name
- NCT02246075
- Testing
- EVP-6124
- Where
- 2 sites in United States
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease Dementia
Alzheimer's Disease THErapy With NEuroaid II
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects…
- Trial name
- ATHENE II (NCT07191028)
- Testing
- MLC 901
- Where
- Singapore
- Volunteers
- 350 people
- Sponsor
- Moleac Pte Ltd.
Alzheimer Disease
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or…
- Trial name
- NCT03019536
- Testing
- LY3303560 - IV, Florbetapir F 18, Flortaucipir F18
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 22 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease
This is a second extension of EM 1000-1 wherein mild/moderate AD subjects who participated in the original study have completed participation in a first extension of 4-months.
- Trial name
- NCT04271163
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Risk Behavior, Cognitive Decline
Multidomain Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help middle-aged to older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors…
- Trial name
- NCT05141578
- Testing
- Luci Coach Assisted Intervention
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- LuciLab
Alzheimer's Disease
Effect of NeuroAD on Alzheimer Patients
Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer for the treatment of Alzheimer patients.
- Trial name
- NCT01825317
- Testing
- NeuroAD
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
- Trial name
- NCT05227118
- Testing
- Elpipodect
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.
Multicenter, prospective, randomised and controlled study to evaluate the medidux™ app during an observation period of 12 weeks (maximum 16 weeks in case of shifts in the initially planned therapy).
- Trial name
- PRO2 (NCT05425550)
- Testing
- medidux™ app
- Where
- Switzerland
- Volunteers
- 196 people
- Sponsor
- Palleos Healthcare GmbH
Alzheimer's Disease
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.
- Trial name
- NCT01066546
- Testing
- Dimebon tablet for oral administration
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Alzheimer's Disease
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
- Trial name
- STAR Extension (NCT02079246)
- Testing
- Idalopirdine 60 mg
- Where
- 258 sites in United States, Argentina and 25 more
- Volunteers
- 1,463 people
- Sponsor
- H. Lundbeck A/S
Memory Disorders, Age-Related, Retention Disorders, Cognitive
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.
- Trial name
- NCT00276510
- Testing
- EGb 761® (Tanakan®)
- Where
- 698 sites in France
- Volunteers
- 2,878 people
- Sponsor
- Ipsen
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up across all four Arms, as…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-FUTURE (NCT04846426)
- Where
- 4 sites in United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease
A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD.
- Trial name
- NCT03720548
- Testing
- LY3372993
- Where
- 11 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer´s Disease
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations in patients with Alzheimer's disease.
- Trial name
- NCT02008513
- Testing
- AFFITOPE® AD02
- Where
- 27 sites in Austria, Croatia and 4 more
- Volunteers
- 194 people
- Sponsor
- Affiris AG